Canaccord Genuity Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6
Canaccord Genuity analyst Richard Close initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Buy rating and announces Price Target of $6.